Levamisole, as a viral vaccine adjuvant, induces robust host defense through the modulation of innate and adaptive immune responses.

ABSTRACT:

Introduction

An effective vaccination policy must be implemented to prevent foot-and-mouth disease (FMD). However, the currently used vaccines for FMD have several limitations, including induction of humoral rather than cellular immune responses.

Methods

To overcome these shortcomings, we assessed the efficacy of levamisole, a small-molecule immunomodulator, as an adjuvant for the FMD vaccine. We conducted in vitro studies using murine peritoneal exudate cells (PECs) and porcine peripheral blood mononuclear cells (PBMCs) and in vivo studies using mice (experimental animals) and pigs (target animals). We evaluated levamisole-mediated modulation of the innate and adaptive immune responses; early, mid-term, and long-term immune-inducing effects; modes of action; a

SUBMITTER: Kim GS 

PROVIDER: S-EPMC11751227 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature